We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2012 by Chantal Van Ongeval, MD, Phd, Universitaire Ziekenhuizen Leuven.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01684735
First Posted: September 13, 2012
Last Update Posted: September 13, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Chantal Van Ongeval, MD, Phd, Universitaire Ziekenhuizen Leuven
  Purpose
Evaluation of the response to chemotherapy in breast cancer patients by the use of Diffusion-weighted magnetic resonance imaging of the breast before the start of chemotherapy, after one and 3 cycles of therapy and at the end of the therapy.

Condition
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation

Resource links provided by NLM:


Further study details as provided by Chantal Van Ongeval, MD, Phd, Universitaire Ziekenhuizen Leuven:

Primary Outcome Measures:
  • Response to chemotherapy [ Time Frame: 1 year ]
    outcome is the results of pathology after chemotherapy and surgery. Data will be collected for a period of 1 year.


Estimated Enrollment: 30
Study Start Date: March 2012
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
women with breast cancer and chemotherapy
women recently diagnosed with breast cancer and selected to start with neo-adjuvant chemotherapy (6 cycles) before surgery/therapy

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
women diagnosed with breast cancer and treated with neo-adjuvant chemotherapy
Criteria

Inclusion Criteria:

  • core biopsy with diagnosis of breast cancer
  • start of neo-adjuvant chemotherapy

Exclusion Criteria:

  • magnetic resonance imaging incompatibility
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01684735


Contacts
Contact: Chantal Van Ongeval, MD,PhD (0)16343746 ext +32 chantal.vanongeval@uzleuven.be

Locations
Belgium
University Hospitals Leuven Recruiting
Leuven, Belgium, 300
Contact: Hilde Vandenhoutte, Phd    (0)16343636    hilde.vandenhoutte@uzleuven.be   
Principal Investigator: Chantal Van Ongeval, MD,Phd         
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Investigators
Principal Investigator: Chantal Van Ongeval, MD, Phd Universitaire Ziekenhuizen Leuven
  More Information

Responsible Party: Chantal Van Ongeval, MD, Phd, MD,Phd, Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT01684735     History of Changes
Other Study ID Numbers: B322201213618
First Submitted: May 14, 2012
First Posted: September 13, 2012
Last Update Posted: September 13, 2012
Last Verified: September 2012

Keywords provided by Chantal Van Ongeval, MD, Phd, Universitaire Ziekenhuizen Leuven:
diffusion-weighted magnetic resonance imaging

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms